Zydus Lifesciences Limited has informed the Exchange about General Updates
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty 100 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences has completed the block acquisition of an 85.6% controlling stake in Amplitude Surgical SA, a French listed company, on July 29, 2025, through its wholly owned subsidiary Zydus MedTech (France) SAS. The total consideration for the block deal was Euro 256.8 million at Euro 6.25 per share. Following this, Zydus will file a mandatory simplified cash tender offer on July 30, 2025, for the remaining shares at the same price, with seven existing shareholders representing 4.7% already committed, pushing Zydus's holding past 90% post-offer. A squeeze-out of minority shareholders and subsequent delisting of Amplitude Surgical from the French stock exchange will follow. The tender offer is expected to open in September 2025, subject to clearance from the French Financial Market Authority (AMF).
This is a major international acquisition for Zydus, expanding its medical technology footprint in Europe with a fully controlled French listed entity. Shareholders should note the Euro 256.8 million outlay and the likelihood of further expenses during the squeeze-out, though the deal strengthens Zydus's medtech vertical and global positioning.